Mike Lazur, Noesis vets form new agency, Lazur Hoyvald Goldstein Partners

Share this article:

Former Torre Lazur McCann Healthcare chief creative director Mike Lazur, and Commonhealth’s Noesis veterans Christian Hoyvald and Steven Goldstein joined forces to become managing partners of a new agency, Lazur Hoyvald Goldstein Partners.

The agency opened the doors to its offices this April in Bridgewater, NJ.

All three partners see brand-building as their principle goal and believe they have a “nice mixture” of backgrounds, the trio told MM&M during a recent phone interview.

Lazur started out as an art director and has been a creative director for most of his more than 30 years in the industry. Hoyvald spent 14 years on the client side, holding positions in senior brand management, finance and market research at Novartis, Bristol-Myers Squibb and Reliant Pharmaceuticals. Four years ago, he joined Noesis ultimately serving as its EVP, director of client services. Goldstein was SVP, creative director at Noesis and a member of the CommonHealth Management committee. He has worked on several award-winning campaigns throughout his 20-year career.

Of the four clients currently signed on with Lazur Hoyvald Goldstein, one is a large chain of diagnostic radiology centers, one is a manufacturer of globally marketed oral specimen collection and diagnostic devices, and another is a long-established manufacturer of prescription dermatological and surgical products.

Share this article:

Email Newsletters

More in News

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?

In sunny world of LASIK marketers, a dark underbelly

In sunny world of LASIK marketers, a dark ...

Last week, the former FDA branch chief who originally approved LASIK machines asked FDA to reconsider its denial last month of his petition to ban these devices.

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.